Put companies on watchlist
APONTIS PHARMA AG
ISIN: DE000A3CMGM5
WKN: A3CMGM
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

APONTIS PHARMA AG · ISIN: DE000A3CMGM5 · EQS - adhoc news (88 News)
Country: Germany · Primary market: Germany · EQS NID: 1692365
31 July 2023 06:40PM

APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024


EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Contract
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024

31-Jul-2023 / 18:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014

APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024

Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion agreement for the product Trixeo will be terminated in 2023 and not continued in 2024. Co-promotion activities by APONTIS PHARMA will be discontinued by the end of October 2023. This cooperation has been in place since April 2021 and was extended annually in each case. The impact on earnings in fiscal 2023 is expected to be minor, as the contractually agreed cap on sales force visits and thus the applicable revenues cap is expected to be only narrowly missed. The expected total revenue for 2023 is approximately EUR 3.0 million.

APONTIS PHARMA is currently in negotiations with several pharmaceutical companies regarding the marketing of corresponding medicinal products within the scope of cooperation 2024 respectively a multi-year cooperation starting 2024. If successfully concluded, the Company expects to generate a comparable earnings contribution in 2024.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA press contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330



End of Inside Information

31-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: ir@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1692365

 
End of Announcement EQS News Service

1692365  31-Jul-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1692365&application_name=news&site_id=boersengefluester_html
Visual performance / price development - APONTIS PHARMA AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.